CD30L Proteins, Antibodies, cDNA Clones Research Reagents

TNFSF8 (TNF Superfamily Member 8) is a protein coding gene located on human chromosome 9q32-q33.1. TNFSF8 is also known as CD153, CD30L, CD30LG and TNLG3A. The human TNFSF8 gene encodes a 26017 Da protein containing 234 amino acids. The TNFSF8 protein is biasedly expressed in lymph node, appendix and other tissues. Among its related pathways are PEDF Induced Signaling and TNF Superfamily - Human Ligand-Receptor Interactions and their Associated Functions. TNFSF8 is related to signaling receptor binding and tumor necrosis factor receptor binding. TNFSF8 is associated with some diseases, including Anaplastic Large Cell Lymphoma and Lymphoma, Hodgkin, Classic.

CD30L Protein (6)

    CD30L Antibody (2)

      CD30L cDNA Clone (51)

      NM_001244.2
      NM_009403.3
      XM_001064723.2
      XM_001099524.1

      CD30L qPCR Primer (2)

      CD30L Lysate (6)

        CD30L Background

        CD30 ligand (CD30L), also known as CD153 and TNFSF8, is a membrane-associated glycoprotein belonging to the TNF superfamily and TNFR superfamily, and is a specific ligand for CD30/TNFRSF8 originally described as a cell surface antigen and a marker for Hodgkin lymphoma and related hematologic malignancies. CD30L is a type-II membrane glycoprotein expressed on activated T cells, stimulated monocyte-macrophages, granulocytes, eosinophils, and some Burkitt-like lymphoma cell lines. CD30L is capable of transducing signals through CD30 on different CD30+ lymphoma cell lines, and mediates pleiotropic biologic effects including cell proliferation, activation, differentiation, as well as cell death by apoptosis. CD30-CD30 ligand interaction has been suggested to have a pathophysiologic role in malignant lymphomas, particularly Hodgkin disease, large cell anaplastic lymphomas and Burkitt lymphomas, and is also involved in activation and functioning of the T cell-dependent immune response. Thus, CD153 and its receptor CD30 are regarded as therapeutic targets in hematologic malignancies, autoimmune and inflammatory diseases.

        CD30L References

        • Hargreaves PG, et al. (2002) Soluble CD30 binds to CD153 with high affinity and blocks transmembrane signaling by CD30. Eur J Immunol. 32(1): 163-73.
        • Blazar BR, et al. (2004) CD30/CD30 ligand (CD153) interaction regulates CD4+ T cell-mediated graft-versus-host disease. J Immunol. 173(5): 2933-41.
        • Oflazoglu E, et al. (2009) Targeting CD30/CD30L in oncology and autoimmune and inflammatory diseases. Adv Exp Med Biol. 647: 174-85.

        Note: Flag® is a registered trademark of Sigma Aldrich Biotechnology LP. It is used here for informational purposes only.